Mature/antigen-pulsed DCs are then co-cultured with tumor-derived CD8+ T cells where they undergo weekly DC re-stimulation until enough TILs are expanded for the desired assay or for therapeutic use [52]. This evidence concerns the gene CD8A and neoplasm.